Krajska nemocnice Liberec a.s.
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
The department is conducting trials that assess antibiotic optimization for serious bacterial infections, aiming to improve cure rates and reduce resistance.
- Clostridioides difficile infection
- Complicated urinary tract infection
- Acute uncomplicated pyelonephritis
Krajska nemocnice Liberec a.s. supports these studies through its specialized infectious‑disease unit.
Cardiovascular Diseases
Research efforts focus on stroke prevention after non‑cardioembolic events and on improving outcomes for patients with acute heart failure.
- Acute ischemic stroke
- High‑risk transient ischemic attack
- Acute heart failure
The Neurologický JIP A unit collaborates closely with cardiology to enroll eligible participants.
Digestive System Diseases
Ongoing studies evaluate novel agents for chronic liver conditions, targeting liver disease therapies that may halt progression and improve liver function.
- Metabolic Dysfunction‑Associated Steatotic Liver Disease
- Non‑alcoholic steatohepatitis
- Primary Biliary Cholangitis
The hospital’s gastroenterology team provides comprehensive care for trial participants.
Female Urogenital Diseases and Pregnancy Complications
Trials in this area explore bladder cancer treatment options for patients with non‑muscle‑invasive disease, including immunotherapy and gene‑based approaches.
- High‑risk BCG‑unresponsive non‑muscle‑invasive bladder cancer
- Intermediate risk non‑muscle invasive bladder cancer
- Non‑muscle invasive bladder cancer with carcinoma in situ
The urology department at Krajska nemocnice Liberec a.s. coordinates patient screening and follow‑up.
Male Urogenital Diseases
Investigators are testing new hormonal and targeted strategies to improve survival in men with advanced prostate cancer, emphasizing prostate cancer therapy.
- Metastatic castration‑resistant prostate cancer
Urologists at the site contribute expertise in disease staging and treatment monitoring.
Neoplasms
A broad oncology portfolio includes studies on breast, lung, and other solid tumors, seeking to enhance outcomes with advanced cancer immunotherapy and targeted combinations.
- Triple‑negative breast cancer
- Hormone‑receptor positive HER2‑negative advanced breast cancer
- Non‑small cell lung cancer
- Small cell lung cancer
- Metastatic castration‑resistant prostate cancer
The comprehensive cancer center at Krajska nemocnice Liberec a.s. enables multidisciplinary trial participation.
Nutritional and Metabolic Diseases
Studies target metabolic liver injury and related disorders, evaluating agents that may reverse steatosis and improve metabolic health, highlighted by metabolic disease research.
- Non‑alcoholic steatohepatitis
- Metabolic Dysfunction‑Associated Steatotic Liver Disease
- Nutritional metabolic disorders
Endocrinology specialists support patient enrollment and metabolic assessments.
Virus Diseases
Clinical programs investigate therapies for chronic viral hepatitis, aiming to achieve viral clearance and liver health, with a focus on viral hepatitis treatment.
- Chronic hepatitis D infection
- Chronic hepatitis B infection
Infectious disease clinicians at the hospital oversee virologic monitoring.
Other Research Areas
Additional projects explore innovative combinations of immunotherapy, targeted agents, and gene‑based therapies across various cancers, reflecting the site’s commitment to innovative therapeutic approaches.
- Combination immunotherapy trials
- Novel targeted agents
- Gene‑based intravesical therapies
The multidisciplinary team at Krajska nemocnice Liberec a.s. facilitates rapid translation of emerging treatments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 107 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 107 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Ferring Pharmaceuticals A/S2active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International6trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Krajska nemocnice Liberec a.s.
lock Showing 1 of 40 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Sep 2023 | Dec 2025 |
IMP list
lock Showing 1 of 107 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 4 | Unknown | 2020-06-09 | 2025-11-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.